SEC Tracker
Get the app

Recursion Pharmaceuticals RXRX

Recursion Pharmaceuticals Q1 FY25: revenue $14.7M, up 7%; diluted EPS −$0.50

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers Recursion Pharmaceuticals reported for Q1 FY25, the quarter ended Mar 31, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$14.7M+7% from $13.8M in Q1 FY2410-Q income statement, on EDGAR
  2. Net income−$202.5MAgainst −$91.4M in Q1 FY2410-Q income statement, on EDGAR
  3. Diluted EPS−$0.50Against −$0.39 in Q1 FY2410-Q income statement, on EDGAR
  4. Cash and cash equivalents$500.5M+69% from $296.3M in Q1 FY2410-Q balance sheet, on EDGAR
  5. Cash from operations−$132.0MAgainst −$102.3M in Q1 FY2410-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Recursion Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Bausch Health Companies BHC public float $2.0B, Jun 30, 2025
  2. Vericel VCEL public float $2.1B, Jun 30, 2025
  3. Agios Pharmaceuticals AGIO public float $1.9B, Jun 30, 2025
  4. Biocryst Pharmaceuticals BCRX public float $1.9B, Jun 30, 2025
  5. Indivior Pharmaceuticals INDV public float $1.8B, Jun 30, 2025